High-Resolution Plasma Metabolomic Profiling to Identify Biomarkers for Tuberculosis Disease and Response to Therapy
高分辨率血浆代谢组学分析可识别结核病生物标志物和治疗反应
基本信息
- 批准号:9300433
- 负责人:
- 金额:$ 24.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-02-14 至 2019-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAgeAmino AcidsAnti-Retroviral AgentsAntitubercular AgentsApplications GrantsBiologicalBiological MarkersBloodCaucasiansCell WallClinical MarkersCommunicable DiseasesCountryCoupledDataDetectionDevelopmentDiagnosisDiagnostic testsDiglyceridesDiseaseDrug-sensitiveFunctional disorderFutureGlycolipidsGoalsHIVHIV SeropositivityHealthHouseholdHumanHybridsIndividualInfectionIonsKnowledgeLeadLinkMetabolicMetabolic PathwayMethodsMultidrug-Resistant TuberculosisMycobacterium tuberculosisOutcomePIM1 genePathway interactionsPatientsPharmaceutical PreparationsPharmacotherapyPhosphatidylglycerolsPhosphatidylinositolsPilot ProjectsPlasmaPulmonary TuberculosisRecoveryRecovery of FunctionRegulationResolutionSamplingSchemeSensitivity and SpecificitySeriesSouth AfricaSouth AfricanSputumTestingTimeTrehaloseTuberculosisValidationattributable mortalitybasecell envelopeco-infectioncohortdesigndisorder controlimprovedlipid mediatorlipid metabolismmass spectrometermetabolic profilemetabolomicsmortalitymycolatenovelpathogenpoint-of-care diagnosticspotential biomarkerpredictive markerrapid detectionresponsesexsmall moleculespecific biomarkerstreatment responsetuberculosis drugstuberculosis treatmentultra high resolution
项目摘要
Summary/abstract: Tuberculosis (TB) is the number one infectious disease killer in the world with 1.5 million
deaths attributable to the disease in 2014. A critical knowledge gap exists given the lack of biological
pathways and predictive biomarkers related to TB onset, progression and resolution. An improved diagnostic
test for TB would have a major impact on global control of the disease and reduce mortality. Unfortunately,
there are no validated biomarkers for TB onset, progression and resolution; the development of a TB
biomarker is urgently needed. Current ultra-high-resolution metabolomics (HRM) methods have considerable
promise for the development of TB-associated biomarkers. Several studies have identified distinguishing small
molecule metabolic profiles in blood and other bio samples in individuals with active Mycobacterium
tuberculosis (Mtb)-induced TB disease compared to uninfected controls, but no studies have explored whether
metabolomics is predictive of TB outcomes, Mtb clearance from sputum. Further, all studies to date have used
low-resolution metabolomics methods. Advances in mass spectrometer machine capability, coupled with
recent advanced data extraction/analysis methods has considerably increased the dynamic range of
metabolite detection by HRM in biologic samples, which now exceeds 20,000 species (>100,000 ions). Our
HRM processing scheme provides capability to detect very low abundance metabolites, including Mtb cell
envelope glycolipids, and explore regulation of human metabolic pathways. In a pilot study, we successfully
identified 61 plasma metabolites that differentiated adults with active pulmonary TB from household contacts
without TB. Differentiating species included specific Mtb-derived cell wall glycolipids and endogenous lipid
mediator resolvins. Our recent pilot data shows that specific metabolites and human metabolic pathways,
including those involved in drug, amino acid, and lipid metabolism, are associated with the propensity for
sputum Mtb culture clearance over time. The ultimate goal of this exploratory proposal is to obtain novel data
that may lead to the development of new TB biomarkers. We hypothesize that plasma HRM analysis can: 1)
predict the propensity for successful anti-TB treatment by identifying Mtb-derived and endogenous metabolites
(biomarkers) and human metabolic pathways (pathophysiology) associated with sputum Mtb clearance; and 2)
successfully differentiate patients with active TB from controls without latent TB infection (LTBI) or TB disease.
To test these hypotheses, we propose the following Specific Aims in this exploratory R21 project:
Specific Aim 1: To determine whether plasma HRM analysis can identify Mtb-derived and endogenous
metabolites that predict clearance of Mtb from sputum (change from positive to negative culture).
Specific Aim 2: To determine whether plasma HRM analysis can differentiate adults with drug-
sensitive or MDR-TB ± HIV co-infection from asymptomatic controls without LTBI.
摘要/摘要:结核病 (TB) 是世界上第一大传染病杀手,有 150 万人罹患结核病
2014 年因该疾病死亡的人数。由于缺乏生物学知识,存在严重的知识差距
与结核病发病、进展和消退相关的途径和预测生物标志物。改进的诊断
结核病检测将对全球控制该疾病并降低死亡率产生重大影响。很遗憾,
对于结核病的发病、进展和消退,没有经过验证的生物标志物;结核病的发展
迫切需要生物标志物。当前的超高分辨率代谢组学(HRM)方法具有相当大的应用价值。
有望开发结核病相关生物标志物。几项研究已经确定了不同的小
活跃分枝杆菌个体血液和其他生物样本中的分子代谢特征
与未感染的对照相比,结核病 (Mtb) 诱发的结核病,但没有研究探讨是否
代谢组学可预测结核病结果以及痰中结核分枝杆菌的清除情况。此外,迄今为止的所有研究都使用
低分辨率代谢组学方法。质谱仪机器能力的进步,加上
最近先进的数据提取/分析方法大大增加了动态范围
通过 HRM 检测生物样品中的代谢物,目前生物样品中的代谢物超过 20,000 种(>100,000 个离子)。我们的
HRM 处理方案提供了检测极低丰度代谢物的能力,包括 Mtb 细胞
包膜糖脂,探索人体代谢途径的调节。在一项试点研究中,我们成功地
鉴定出 61 种血浆代谢物,可将患有活动性肺结核的成人与家庭接触者区分开来
无结核病。区分物种包括特定的结核分枝杆菌衍生的细胞壁糖脂和内源性脂质
调解员解决。我们最近的试点数据表明,特定的代谢物和人类代谢途径,
包括那些涉及药物、氨基酸和脂质代谢的物质,与以下倾向相关:
随着时间的推移,痰 Mtb 培养物会被清除。这个探索性提案的最终目标是获得新数据
这可能会导致新的结核病生物标志物的开发。我们假设血浆 HRM 分析可以:1)
通过识别结核分枝杆菌衍生的和内源性代谢物来预测成功抗结核治疗的倾向
与痰 Mtb 清除相关的(生物标志物)和人类代谢途径(病理生理学);和 2)
成功区分活动性结核病患者与没有潜伏性结核病感染 (LTBI) 或结核病的对照患者。
为了检验这些假设,我们在这个探索性 R21 项目中提出以下具体目标:
具体目标 1:确定血浆 HRM 分析是否可以识别 Mtb 源性和内源性
预测痰液中 Mtb 清除率的代谢物(从阳性培养物变为阴性培养物)。
具体目标 2:确定血浆 HRM 分析是否可以区分成人药物-
来自无 LTBI 的无症状对照的敏感或 MDR-TB ± HIV 双重感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dean Paul Jones其他文献
Dean Paul Jones的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dean Paul Jones', 18)}}的其他基金
Mega-scale Identification tools for xenobiotic metabolism
外源代谢的大规模鉴定工具
- 批准号:
10201601 - 财政年份:2018
- 资助金额:
$ 24.07万 - 项目类别:
Mega-scale Identification tools for xenobiotic metabolism
外源代谢的大规模鉴定工具
- 批准号:
9769022 - 财政年份:2018
- 资助金额:
$ 24.07万 - 项目类别:
Mega-scale Identification tools for xenobiotic metabolism
外源代谢的大规模鉴定工具
- 批准号:
9981744 - 财政年份:2018
- 资助金额:
$ 24.07万 - 项目类别:
High-Resolution Plasma Metabolomic Profiling to Identify Biomarkers for Tuberculosis Disease and Response to Therapy
高分辨率血浆代谢组学分析可识别结核病生物标志物和治疗反应
- 批准号:
9432482 - 财政年份:2017
- 资助金额:
$ 24.07万 - 项目类别:
Georgia Comprehensive Metabolomics and Proteomics Unit for MoTrPAC
佐治亚州 MoTrPAC 综合代谢组学和蛋白质组学单位
- 批准号:
9246760 - 财政年份:2016
- 资助金额:
$ 24.07万 - 项目类别:
Metabolomics of subclinical and clinical cardiovascular disease
亚临床和临床心血管疾病的代谢组学
- 批准号:
8625332 - 财政年份:2012
- 资助金额:
$ 24.07万 - 项目类别:
Metabolomics of subclinical and clinical cardiovascular disease
亚临床和临床心血管疾病的代谢组学
- 批准号:
8286494 - 财政年份:2012
- 资助金额:
$ 24.07万 - 项目类别:
Metabolomics of subclinical and clinical cardiovascular disease
亚临床和临床心血管疾病的代谢组学
- 批准号:
8463610 - 财政年份:2012
- 资助金额:
$ 24.07万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 24.07万 - 项目类别:
Research Grant